Literature DB >> 18160417

Cardiovascular risk factors in adult patients with multisystem Langerhans-cell histiocytosis: evidence of glucose metabolism abnormalities.

K I Alexandraki1, P Makras, A D Protogerou, K Dimitriou, A Stathopoulou, D S Papadogias, P Voidonikola, G Piaditis, A Pittas, C M Papamichael, A B Grossman, G Kaltsas.   

Abstract

BACKGROUND: Langerhans-cell histiocytosis (LCH) is a rare disease with features of chronic inflammation and it may also induce hypopituitarism, conditions associated with an increased risk of cardiovascular diseases. AIM: Cardiovascular and metabolic risk profile investigation in multisystem LCH patients with and without anterior pituitary deficiency.
DESIGN: Prospective, observational study.
METHODS: Fourteen adult patients with LCH, 7 with and 7 without anterior pituitary deficiency, and 42 controls matched for age, body mass index (BMI) and smoking. Cardiovascular risk factors were estimated in all subjects: glucose and lipid profile, mathematical indices of insulin resistance (IR), blood pressure, structural arterial and functional endothelial properties (intima-media thickness, brachial artery flow-mediated dilatation). Cardiovascular risk factors were estimated in the three groups studied; the effect of disease activity and/or treatment was also determined in patients with LCH.
RESULTS: Ten patients had diabetes insipidus, and 7 anterior pituitary hormone deficiencies: 8 patients had active disease and 11 had received systemic treatment. No difference was observed between the study groups in vascular parameters, in lipid profile or in blood pressure. However, the insulin resistance index GIR was decreased in patients with LCH without anterior pituitary deficiency compared to controls (P = 0.033). Three patients had impaired glucose tolerance and one diabetes mellitus type 2. These patients were older and had active disease; there was no association with hypopituitarism and/or previous treatment.
CONCLUSION: Adults patients with LCH have abnormalities of glucose metabolism that tend to occur in patients with active disease, and may be a consequence of the pro-inflammatory state.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160417     DOI: 10.1093/qjmed/hcm118

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  4 in total

1.  Hyperosmolar coma in a patient with hypothalamic Langerhans cell histiocytosis.

Authors:  Ivan Kruljac; Goran Rinčić; Hrvoje Ivan Pećina
Journal:  Endocrine       Date:  2015-07-07       Impact factor: 3.633

2.  Diabetes Mellitus, Extreme Insulin Resistance, and Hypothalamic-Pituitary Langerhans Cells Histiocytosis.

Authors:  Mathilde Sollier; Marine Halbron; Jean Donadieu; Ahmed Idbaih; Fleur Cohen Aubart; Corinne Vigouroux; Martine Auclair; Olivier Bourron; Marie Bastin; Géraldine Béra; Philippe Touraine; Jacques Young; Héléna Mosbah; Agnès Hartemann; Fabrizio Andreelli; Chloé Amouyal
Journal:  Case Rep Endocrinol       Date:  2019-06-23

Review 3.  Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net.

Authors:  Michael Girschikofsky; Maurizio Arico; Diego Castillo; Anthony Chu; Claus Doberauer; Joachim Fichter; Julien Haroche; Gregory A Kaltsas; Polyzois Makras; Angelo V Marzano; Mathilde de Menthon; Oliver Micke; Emanuela Passoni; Heinrich M Seegenschmiedt; Abdellatif Tazi; Kenneth L McClain
Journal:  Orphanet J Rare Dis       Date:  2013-05-14       Impact factor: 4.123

4.  Pulmonary Langerhans Cell Histiocytosis in an Adult Male Presenting with Central Diabetes Insipidus and Diabetes Mellitus: A Case Report.

Authors:  Yeun Seoung Choi; Jung Soo Lim; Woocheol Kwon; Soon-Hee Jung; Il Hwan Park; Myoung Kyu Lee; Won Yeon Lee; Suk Joong Yong; Seok Jeong Lee; Ye-Ryung Jung; Jiwon Choi; Ji Sun Choi; Joon Taek Jeong; Jin Sae Yoo; Sang-Ha Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2015-10-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.